{"title":"无丙型肝炎内窥镜程序项目:一种院内消除方法。","authors":"Benjamin Lih-Ren Hsieh, Yen-Ting Kuo, Yu-Ju Wei, Pei-Chien Tsai, Ming-Lun Yeh, Chung-Feng Huang, Chia-Yen Dai, Ming-Yen Hsieh, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang","doi":"10.1002/kjm2.12942","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatitis C virus (HCV) elimination in the care cascades for patients receiving invasive procedures remains elusive. This study aimed to evaluate the efficacy of HCV-free Endoscope Procedures Project (CEPP) in the effort toward hospital HCV micro-elimination in Taiwan. An electronic medical record (EMR)-based remind system was introduced into gastrointestinal, surgical, urological, and gynecological departments prior to the endoscopy procedures. Anti-HCV tests were actively ordered on their EMR among those patients who have not been tested in the past 5 years. Those patients with anti-HCV+ were recruited into the care cascade for HCV treatment, including HCVRNA testing, direct antivirals (DAAs) delivery, and treatment response assessment. We divided the elimination project into two phases: before (2020 Jan to 2020 Dec, phase A) and during (2021 Jan to 2022 Sep, phase B) the remind system. The screening rate of phase B was 64.2% (1857/2893), which was significantly higher than phase A (18.7%, 899/4812) (p < 0.001). The screening rate of Department of Medicine (DOM) significantly increased from 21.1% of phase A to 89.3% of Phase B (p < 0.001). During phase B, the screening rate of non-DOM was 48.2%, which was significantly higher than 11.8% of Phase A (p < 0.001). During Phase B, 15 (0.8%) out of 1857 screened patients were HCVRNA+. Six HCVRNA+ patients received DAAs treatment, and all achieved viral eradication. The CEPP significantly increased the anti-HCV screening rate for subsequent care cascades, particularly in patients of DOM.</p>","PeriodicalId":94244,"journal":{"name":"The Kaohsiung journal of medical sciences","volume":" ","pages":"e12942"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hepatitis C virus-free endoscope procedures project: An in-hospital elimination approach.\",\"authors\":\"Benjamin Lih-Ren Hsieh, Yen-Ting Kuo, Yu-Ju Wei, Pei-Chien Tsai, Ming-Lun Yeh, Chung-Feng Huang, Chia-Yen Dai, Ming-Yen Hsieh, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang\",\"doi\":\"10.1002/kjm2.12942\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hepatitis C virus (HCV) elimination in the care cascades for patients receiving invasive procedures remains elusive. This study aimed to evaluate the efficacy of HCV-free Endoscope Procedures Project (CEPP) in the effort toward hospital HCV micro-elimination in Taiwan. An electronic medical record (EMR)-based remind system was introduced into gastrointestinal, surgical, urological, and gynecological departments prior to the endoscopy procedures. Anti-HCV tests were actively ordered on their EMR among those patients who have not been tested in the past 5 years. Those patients with anti-HCV+ were recruited into the care cascade for HCV treatment, including HCVRNA testing, direct antivirals (DAAs) delivery, and treatment response assessment. We divided the elimination project into two phases: before (2020 Jan to 2020 Dec, phase A) and during (2021 Jan to 2022 Sep, phase B) the remind system. The screening rate of phase B was 64.2% (1857/2893), which was significantly higher than phase A (18.7%, 899/4812) (p < 0.001). The screening rate of Department of Medicine (DOM) significantly increased from 21.1% of phase A to 89.3% of Phase B (p < 0.001). During phase B, the screening rate of non-DOM was 48.2%, which was significantly higher than 11.8% of Phase A (p < 0.001). During Phase B, 15 (0.8%) out of 1857 screened patients were HCVRNA+. Six HCVRNA+ patients received DAAs treatment, and all achieved viral eradication. The CEPP significantly increased the anti-HCV screening rate for subsequent care cascades, particularly in patients of DOM.</p>\",\"PeriodicalId\":94244,\"journal\":{\"name\":\"The Kaohsiung journal of medical sciences\",\"volume\":\" \",\"pages\":\"e12942\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Kaohsiung journal of medical sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/kjm2.12942\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Kaohsiung journal of medical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/kjm2.12942","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Hepatitis C virus-free endoscope procedures project: An in-hospital elimination approach.
Hepatitis C virus (HCV) elimination in the care cascades for patients receiving invasive procedures remains elusive. This study aimed to evaluate the efficacy of HCV-free Endoscope Procedures Project (CEPP) in the effort toward hospital HCV micro-elimination in Taiwan. An electronic medical record (EMR)-based remind system was introduced into gastrointestinal, surgical, urological, and gynecological departments prior to the endoscopy procedures. Anti-HCV tests were actively ordered on their EMR among those patients who have not been tested in the past 5 years. Those patients with anti-HCV+ were recruited into the care cascade for HCV treatment, including HCVRNA testing, direct antivirals (DAAs) delivery, and treatment response assessment. We divided the elimination project into two phases: before (2020 Jan to 2020 Dec, phase A) and during (2021 Jan to 2022 Sep, phase B) the remind system. The screening rate of phase B was 64.2% (1857/2893), which was significantly higher than phase A (18.7%, 899/4812) (p < 0.001). The screening rate of Department of Medicine (DOM) significantly increased from 21.1% of phase A to 89.3% of Phase B (p < 0.001). During phase B, the screening rate of non-DOM was 48.2%, which was significantly higher than 11.8% of Phase A (p < 0.001). During Phase B, 15 (0.8%) out of 1857 screened patients were HCVRNA+. Six HCVRNA+ patients received DAAs treatment, and all achieved viral eradication. The CEPP significantly increased the anti-HCV screening rate for subsequent care cascades, particularly in patients of DOM.